Merck & Co., Inc. Share-based Payment Arrangement, Expense
Merck & Co., Inc. (MRK) reported Share-based Payment Arrangement, Expense of $498.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2024-02-26
- Merck & Co., Inc. share-based payment arrangement, expense for the quarter ending 2011-09-30 was $86.00M, a 31.20% decline year-over-year.
- Merck & Co., Inc. share-based payment arrangement, expense for the quarter ending 2011-06-30 was $107.00M, a 24.65% decline year-over-year.
- Merck & Co., Inc. share-based payment arrangement, expense for the quarter ending 2011-03-31 was $93.00M, a 29.55% decline year-over-year.
- Merck & Co., Inc. share-based payment arrangement, expense for the quarter ending 2010-09-30 was $125.00M, a 47.58% increase year-over-year.
- Merck & Co., Inc. share-based payment arrangement, expense for fiscal 2021 was $498.00M, a 4.84% increase from fiscal 2020.
- Merck & Co., Inc. share-based payment arrangement, expense for fiscal 2020 was $475.00M, a 13.91% increase from fiscal 2019.
- Merck & Co., Inc. share-based payment arrangement, expense for fiscal 2019 was $417.00M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $498.00M 10-K · filed 2024-02-26 | ||||||
| 2020-12-31 | $475.00M 10-K · filed 2023-02-24 | ||||||
| 2019-12-31 | $417.00M 10-K · filed 2022-02-25 | ||||||
| 2011-09-30 | $86.00M 10-Q · filed 2011-11-08 | $193.00M derived: sum of 2 quarters · filed 2011-11-08 | $287.00M 10-Q · filed 2011-11-08 | ||||
| 2011-06-30 | $107.00M 10-Q · filed 2011-08-08 | $200.00M 10-Q · filed 2011-08-08 | |||||
| 2011-03-31 | $93.00M 10-Q · filed 2011-05-09 | ||||||
| 2010-09-30 | $125.00M 10-Q · filed 2011-11-08 | $125.30M 10-Q · filed 2010-11-08 | $267.00M derived: sum of 2 quarters · filed 2011-11-08 | $400.00M 10-Q · filed 2011-11-08 | $399.50M 10-Q · filed 2010-11-08 | ||
| 2010-06-30 | $142.00M 10-Q · filed 2011-08-08 | $141.80M 10-Q · filed 2010-08-06 | $274.00M 10-Q · filed 2011-08-08 | $274.20M 10-Q · filed 2010-08-06 | |||
| 2010-03-31 | $132.00M 10-Q · filed 2011-05-09 | ||||||
| 2009-09-30 | $84.70M 10-Q · filed 2010-11-08 | $168.50M derived: sum of 2 quarters · filed 2010-11-08 | $281.80M 10-Q · filed 2010-11-08 | ||||
| 2009-06-30 | $83.80M 10-Q · filed 2010-08-06 | $197.10M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |